What are the treatment guidelines for chronic HCV infection in genotype 3 patients previously treated with a DDA?

Updated: Oct 07, 2019
  • Author: Vinod K Dhawan, MD, FACP, FRCPC, FIDSA; Chief Editor: BS Anand, MD  more...
  • Print

HCV genotype 3 DAA treatment-experienced (including NS5A inhibitors) patients with or without compensated cirrhosis

Recommended regimens

  • Daily fixed-dose combination of sofosbuvir (400 mg)/velpatasvir (100 mg)/voxilaprevir (100 mg) for 12 weeks
  • Weight-based ribavirin for 12 weeks for individuals with prior NS5A inhibitor failure and cirrhosis

Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!